2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study

Background: Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influe...

Descripción completa

Detalles Bibliográficos
Autores: Rondy M, Puig-Barbera J, Launay O, Duval X, Castilla J, Guevara M, Costanzo S, de Gaetano Donati K, Moren A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p3442
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/3442
Access Level:acceso abierto
id ES_44cddd2a10d2cb8f4974c7a2a03cfe75
oai_identifier_str oai:fisabio.fundanetsuite.com:p3442
network_acronym_str ES
network_name_str España
repository_id_str
spelling 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot StudyRondy MPuig-Barbera JLaunay ODuval XCastilla JGuevara MCostanzo Sde Gaetano Donati KMoren ABackground: Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influenza vaccine effectiveness (IVE) against severe outcomes. We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union. Methods: We conducted a multicentre study in France (seven hospitals), Italy (one hospital), and Navarra (four hospitals) and Valencia (nine hospitals) regions in Spain. All >= 18 years hospitalised patients presenting an influenza-like illness within seven days were swabbed. Cases were patients RT-PCR positive for influenza A (H3N2); controls were patients negative for any influenza virus. Using logistic regression with study site as a fixed effect we calculated IVE adjusted for potential confounders. We restricted the analyses to those swabbed within four days. Results: We included, 375 A(H3N2) cases and 770 controls. The overall adjusted IVE was 24.9% (95% CI-1.8; 44.6). Among the target group for vaccination (N = 1058) the adjusted IVE was 28.8% (95% CI: 2.8; 47.9); it was respectively 36.8% (95% CI: 248.8; 73.1), 42.6% (95% CI: 216.5; 71.7), 17.8%(95% CI: 240.8; 52.1) and 37.5% (95% CI: 222.8;68.2) in the age groups 18-64, 65-74, 75-84 and more than 84 years. Discussion: Estimation of IVE based on the pooling of data obtained through a European network of hospitals was feasible. Our results suggest a low IVE against hospitalised confirmed influenza in 2011-12. The low IVE may be explained by a poor immune response in the high-risk population, imperfect match between vaccine and circulating strain or waning immunity due to a late season. Increased sample size within this network would allow more precise estimates and stratification of the IVE by time since vaccination and vaccine types or brands.PUBLIC LIBRARY SCIENCE2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/3442PLoS OneISSN: 19326203reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p34422026-06-11T12:45:17Z
dc.title.none.fl_str_mv 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
title 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
spellingShingle 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
Rondy M
title_short 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
title_full 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
title_fullStr 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
title_full_unstemmed 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
title_sort 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
dc.creator.none.fl_str_mv Rondy M
Puig-Barbera J
Launay O
Duval X
Castilla J
Guevara M
Costanzo S
de Gaetano Donati K
Moren A
author Rondy M
author_facet Rondy M
Puig-Barbera J
Launay O
Duval X
Castilla J
Guevara M
Costanzo S
de Gaetano Donati K
Moren A
author_role author
author2 Puig-Barbera J
Launay O
Duval X
Castilla J
Guevara M
Costanzo S
de Gaetano Donati K
Moren A
author2_role author
author
author
author
author
author
author
author
description Background: Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influenza vaccine effectiveness (IVE) against severe outcomes. We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union. Methods: We conducted a multicentre study in France (seven hospitals), Italy (one hospital), and Navarra (four hospitals) and Valencia (nine hospitals) regions in Spain. All >= 18 years hospitalised patients presenting an influenza-like illness within seven days were swabbed. Cases were patients RT-PCR positive for influenza A (H3N2); controls were patients negative for any influenza virus. Using logistic regression with study site as a fixed effect we calculated IVE adjusted for potential confounders. We restricted the analyses to those swabbed within four days. Results: We included, 375 A(H3N2) cases and 770 controls. The overall adjusted IVE was 24.9% (95% CI-1.8; 44.6). Among the target group for vaccination (N = 1058) the adjusted IVE was 28.8% (95% CI: 2.8; 47.9); it was respectively 36.8% (95% CI: 248.8; 73.1), 42.6% (95% CI: 216.5; 71.7), 17.8%(95% CI: 240.8; 52.1) and 37.5% (95% CI: 222.8;68.2) in the age groups 18-64, 65-74, 75-84 and more than 84 years. Discussion: Estimation of IVE based on the pooling of data obtained through a European network of hospitals was feasible. Our results suggest a low IVE against hospitalised confirmed influenza in 2011-12. The low IVE may be explained by a poor immune response in the high-risk population, imperfect match between vaccine and circulating strain or waning immunity due to a late season. Increased sample size within this network would allow more precise estimates and stratification of the IVE by time since vaccination and vaccine types or brands.
publishDate 2013
dc.date.none.fl_str_mv 2013
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/3442
url https://fisabio.portalinvestigacion.com/publicaciones/3442
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv PUBLIC LIBRARY SCIENCE
publisher.none.fl_str_mv PUBLIC LIBRARY SCIENCE
dc.source.none.fl_str_mv PLoS One
ISSN: 19326203
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407118608564224
score 15,812455

Similares en LA Referencia